Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines Corporation employs 420 staff and has a trailing 12-month revenue of around USD$811.2 million.
|Latest market close||USD$107|
|52-week range||USD$43.29 - USD$125.61|
|50-day moving average||USD$107.7771|
|200-day moving average||USD$88.6737|
|Wall St. target price||USD$118.27|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$6.178|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||0.15%|
|1 month (2020-12-15)||-9.60%|
|3 months (2020-10-15)||6.65%|
|6 months (2020-07-15)||33.58%|
|1 year (2020-01-15)||33.32%|
|2 years (2019-01-15)||61.75%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-15)||505.20%|
Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Blueprint Medicines Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Blueprint Medicines Corporation shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$331.8 million.
The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$811.2 million|
|Operating margin TTM||40.1%|
|Gross profit TTM||USD$-264,938,000|
|Return on assets TTM||17.71%|
|Return on equity TTM||36.29%|
|Market capitalisation||USD$6.9 billion|
TTM: trailing 12 months
There are currently 3.1 million Blueprint Medicines Corporation shares held short by investors – that's known as Blueprint Medicines Corporation's "short interest". This figure is 4.9% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Blueprint Medicines Corporation shares can be evaluated.
Blueprint Medicines Corporation's "short interest ratio" (SIR) is the quantity of Blueprint Medicines Corporation shares currently shorted divided by the average quantity of Blueprint Medicines Corporation shares traded daily (recently around 529349.31740614). Blueprint Medicines Corporation's SIR currently stands at 5.86. In other words for every 100,000 Blueprint Medicines Corporation shares traded daily on the market, roughly 5860 shares are currently held short.
However Blueprint Medicines Corporation's short interest can also be evaluated against the total number of Blueprint Medicines Corporation shares, or, against the total number of tradable Blueprint Medicines Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Blueprint Medicines Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Blueprint Medicines Corporation shares in existence, roughly 60 shares are currently held short) or 0.0648% of the tradable shares (for every 100,000 tradable Blueprint Medicines Corporation shares, roughly 65 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Blueprint Medicines Corporation.
Find out more about how you can short Blueprint Medicines Corporation stock.
We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $43.29 up to $125.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.8861. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.